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Objective. To examine the effects of a community-based intervention on decisions
about prostate-specific antigen (PSA) screening using multiple measures of informed
decision making (IDM).
Data Sources/Study Setting. Nonequivalent control group time series design
collecting primary data in late 2004 and 2005.
Study Design. We developed a multimodal intervention designed to convey the
medical uncertainty about the benefits of PSA screening and early treatment and the
limited predictive ability of both the PSA test and pathological specimens collected from
prostate biopsy. We examined (1) patients’ recognition that there is a decision to be
made about PSA screening, (2) prostate cancer knowledge levels, (3) their preferred and
actual levels of participation in decision making about screening at three points in time,
and (4) screening decision.
Data Collection. Baseline data collection occurred in community-based organiza-
tions. These organizations served as recruiting sources and as sites for the intervention.
We collected follow-up data by mail with telephone reminders.
Principal Findings. Our intervention was associated with greater recognition of the
PSA test as a decision to be made, levels of knowledge, both preferred and actual levels of
involvement in decision making, but did not have an impact on the screening decision.
Conclusions. Community-based interventions can influence key measures of IDM
about PSA screening.
Key Words. Decision making, prostate cancer screening, level of involvement,
patient–provider communication
BACKGROUND
In 2001–2002, the U.S. Preventive Services Task Force (USPSTF) conducted a
systematic review of the evidence and concluded that it was insufficient to




determine whether the benefits of prostate-specific antigen (PSA) screening
outweigh the harms (Harris and Lohr 2002; USPSTF 2002). According
to a 2008 update of the evidence, whether PSA screening reduces mortality
from prostate cancer still remains unclear (Andriole et al. 2009). PSA
screening can trigger a rapid sequence of further testing and treatment that
often produces significant negative consequences (urinary incontinence and
erectile dysfunction in particular) (USPSTF 2002). Given these uncertainties,
professional associations (Ferrini and Woolf 1998; American Urological As-
sociation 2000; Wolf et al. 2010) widely recommend engaging men in in-
formed decision making (IDM) for PSA screening decisions to ensure that
they understand the uncertain benefits and potential harms associated with
screening.
Despite the lack of clear evidence regarding the benefits of routine
PSA screening, the practice is widespread in the United States; and
testing frequently occurs without adequate discussion between patients
and health professionals (Han et al. 2006; Guerra et al. 2007; Sirovich,
Schwartz, and Woloshin 2007). The 2000 National Health Interview
Survey found physicians often initiate PSA screening without prior discus-
sion with patients about its advantages and disadvantages (Han et al. 2006).
Recipients of PSA screening are often unaware that they have been tested
(Volk and Cass 2002; Chan et al. 2004). Together, these findings suggest that
men’s opportunities to make informed decisions about PSA screening are
constrained.
Because of the scientific uncertainty and general consensus that an
IDM approach is needed, considerable work has gone into developing
decision aids and other interventions to facilitate informed choices about
PSA screening (Rimer et al. 2004; Evans et al. 2005; O’Connor et al. 2006).
IDM interventions for PSA screening increased knowledge, but their
effects on PSA screening uptake are mixed (Rimer et al. 2004; Evans et al.
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2005; O’Connor et al. 2006). In one meta-analysis, use of PSA decision
aids reduced screening uptake (Evans et al. 2005). Another meta-
analysis (Volk et al. 2007) reported that PSA decision aids appeared to de-
crease interest in PSA testing and screening behavior among patients
seeking routine care and had no impact on the screening behavior
of patients seeking screening services. Evaluations of IDM interventions in
general (not specific to prostate cancer) find that they increase knowledge
and accuracy of risk perceptions, although effects are often not sustained
over longer follow-up (Rimer et al. 2004; Evans et al. 2005). IDM interven-
tions also influence participants’ preferences for an active role in decision
making and increase satisfaction with the decision-making process (O’Connor
et al. 2006).
Patient preferences for involvement in decision making vary
along a spectrum from, at one end, a clinician-controlled (paternalistic)
model in which the patient relies on the clinician to make decisions to,
at the other, a preference for autonomous decision making (Robinson and
Thompson 2001; Flynn, Smith, and Vanness 2006; Ryan and Sysko 2007;
Thompson 2007). Role preferences in decision making differ by the type
and severity of the illness, patient characteristics, and patients’ relationships
with health professionals. A preference for greater autonomy in decision
making is generally associated with younger age, higher educational attain-
ment, and better health status (Benbassat, Pilpel, and Tidhar 1998; Robinson
and Thompson 2001; Flynn, Smith, and Vanness 2006; Ryan and Sysko
2007).
No single metric reflecting IDM exists. Most evaluations of IDM inter-
ventions have assessed knowledge and screening intention and behavior
(Rimer et al. 2004; Mullen et al. 2006). Few studies have examined a broader
range of outcomes including participation in decision making at a level con-
sistent with the patient’s personal preference or satisfaction with the decision-
making process (Rimer et al. 2004; Evans et al. 2005; O’Connor et al. 2006;
Mullen et al. 2006). To advance understanding of IDM in cancer screening,
Mullen et al. (2006) recommend that studies use rigorous measures of (1)
patients’ participation in decision making at the level they desire, (2) consis-
tency between personal values and screening decisions, and (3) satisfaction
with the decision-making process and the decision made.
This is one of the first studies to implement a full range of IDM measures
advocated by Mullen et al. (2006) along with other measures in an intervention
study examining decision making about PSA screening. Specifically, we inves-
tigated the intervention’s effects on men’s beliefs that they have a decision to make
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about PSA screening (a necessary prerequisite to IDM), their knowledge levels,
their preferred and actual levels of involvement in the decision of whether
to have a PSA screening test (and concordance between the two),
and their satisfaction with level of involvement and the decisions made. We
used a community-based IDM intervention approach; it offers distinct advan-
tages over clinic-based IDM promotion yet has rarely been implemented and
evaluated.
STUDY DESIGN
We conducted an intervention study designed to promote IDM about PSA
screening in three communities. The study received human subjects approval
from the institutions involved.
Setting and Participants
We identified and defined the communities using an in-depth comparison
process involving sociodemographic and economic comparability data (see
Driscoll et al. 2008 for more information).
The baseline data collection took place within community-based orga-
nizations (e.g., senior, faith-based, fraternal, fitness, and recreational organi-
zations) in two North Carolina communities; a third North Carolina
community served as a control population. The community-based organiza-
tions served both as recruiting sources and as physical sites for delivering the
intervention. Organizations advertised the intervention and data collection
sessions to their members and others in the community primarily using flyers
and word of mouth.
Intervention
The study team delivered a total of 20 intervention sessions, with 10–30 male
participants per session, between September 2004 and February 2005. Our
multicomponent intervention comprised an oral scripted presentation by a
community physician followed by a question-and-answer session, a 20-minute
video, a website, and print materials, including a trifold brochure, a 4  6-in.
poster, and a shirt-pocket card decision aid (see Soloe et al. 2009 for a
detailed description of the intervention rationale, theoretical foundation,
images of the materials, formative research process including iterative
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development using multiple rounds of pretesting). The key intervention mes-
sages were as follows:
 there are two types of prostate cancers: slow growing and fast
growing;
 a problem with the PSA test is that it leads some men with slow-
growing prostate cancer to get treatment they do not need;
 about half of all men who get treatment for prostate cancer will have
permanent side effects; and
 men should decide whether they feel the PSA test is right for them
and talk with their physicians.
The final messages do not focus on the potential benefits of PSA screen-
ing. We originally presented equal amounts of information about the pros and
cons of screening. However, extensive formative message testing of the orig-
inal messages revealed cognitive dissonance for men associated with a mes-
sage that (1) promotes IDM while (2) also conveying the potential (not the
certainty) that screening might reduce risk of death (Driscoll and Harris-
Kojetin 2002; Soloe et al. 2009). That kind of complex message was not well
understood because of the challenge associated with explaining medical
uncertainty to a lay audience. The final intervention materials also contain
information about risk factors for prostate cancer and different treatment op-
tions, and they encourage men to think about what choices are right for them
based on their preferences and values. We developed two versions of the
intervention materials: Prostate Only (PO) and Men’s Health (MH). The MH
version gave additional information about other common preventive health
screening for men and highlighted the certainty in benefit from these screen-
ing tests. The materials contained no restrictions or guidance regarding which
physicians study participants could or should see for their health care. Study
participants could not be linked to provider-level data.
Data Collection Procedures
Only men between 40 and 80 years of age and not diagnosed previously with
prostate cancer were invited to participate in the study. In the intervention
communities, men attending the intervention sessions completed a self-
administered baseline survey immediately before the intervention session.
After the intervention, which lasted 45 minutes on average, men completed a
shorter, immediate posttest survey intended to capture their impressions of the
intervention. Approximately 6 and 12 months following the intervention, we
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conducted follow-up surveys by mail. Follow-up data collection was staggered
over several months because of the schedules of the community-based orga-
nizations. In the control community, we conducted the baseline survey in-
person and the remaining surveys by mail following the same schedule as in
the intervention communities. Study participants received U.S.$10 for their
time after completing each follow-up survey (see Driscoll et al. 2008 for ad-
ditional information on data collection procedures).
Key Measures and Hypotheses
We tested whether the intervention affected men’s belief that they have a
decision to make about PSA screening, thus establishing the groundwork for
making informed decisions. We hypothesized that the intervention would
increase men’s knowledge levels and their preferred and actual levels of in-
volvement in the screening decision and raise the concordance between the
preferred and actual levels. We also examined possible sociodemographic
differences and psychosocial correlates of the study outcomes.
Main Outcomes Measures on the Survey
Belief That PSA Screening Is a Decision. We asked for men’s level of agreement
with a series of four statements to assess the extent to which they believed that
PSA screening is a decision to be made. Three items were in the baseline and
6-month surveys. For the 12-month survey, we added a fourth item (a man
between the ages of 50 and 70 in average health who decides not to have an
annual PSA test is irresponsible) to reflect a similar measure in a
contemporaneous national survey (Schwartz et al. 2004). We created the
‘‘PSA is a Decision’’ composite score based on responses to three of the items
(Cronbach’s a5 0.76).
Knowledge of Prostate Cancer Screening and Treatment. The survey included 10
knowledge questions in all three surveys designed to assess respondents’
understanding of the intervention content; they were based partly on work by
Radosevich et al. (2004) (e.g., possible reasons for a high PSA test, which type
of treatment works best, common side effects from treatment). We coded
responses as correct or incorrect (‘‘don’t know’’ as incorrect) and computed a
knowledge index score (range 0–10; Cronbach’s a5 0.70).
Preferred Level of Involvement in PSA Decision. To assess men’s preferences
related to participation in the PSA screening decision and changes over time,
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we adapted a validated survey item from Degner, Sloan, and Venkatesh
(1997). We grouped the five response options below as indicated for a logistic
regression analyses:
 I prefer to leave all decisions to my doctor.
More passive I prefer that my doctor make the final decision
but seriously consider my opinion.




 I prefer to make the final decision after seriously
considering my doctor’s opinion.
 I prefer to make the final decision.
Actual Level of Involvement in PSA Decision. We asked a parallel question in the
6- and 12-month follow-up surveys to assess men’s actual involvement in the
PSA decision. However, at 6 months, this question was asked only of men who
had discussed PSA screening with their provider. The percentage of men who
had a discussion with their provider at 6 months was 55 percent (and 59
percent at 12 months).
Concordance between Preferred and Actual Levels of Involvement in the PSA
Decision. We created a ‘‘concordance’’ (or ‘‘preference match’’; Kiesler
and Auerbach 2006) measure based on the match between partici-
pants’ preferred and actual levels of involvement in the PSA decision
at the same measurement points (i.e., match between preferred and
actual levels of involvement at 6- or 12-month follow-up). We classified
participants who selected parallel response options for both questions
as concordant. At 6 months, we applied the concordance measure only
to men who had discussed PSA screening with their physician because
only these men had been asked about their actual level of involvement at
that point.
Satisfaction with Involvement in Decision Making and Decision Made. At 12
months, we asked respondents about their screening decision, how satisfied
they were with their actual level of involvement, and how satisfied they were
with their decision.
Other Measures
Sociodemographic and health variables were measured at baseline. Because
we anticipated that the intervention might affect other variables, we used
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men’s responses to all other measures at the 12-month follow-up to examine
the effects of recent experience and of knowledge on the outcomes of interest.
Self-Efficacy for Communicating with a Physician. We developed a composite
self-efficacy score based on the mean responses to three questions about how
well respondents felt their physician answered all their questions, listened
carefully to them, and explained things in a way they could understand
(Cronbach’s a5 0.89).
Decisional Uncertainty. We administered an adaptation of the decisional
uncertainty subscale from the Decisional Conflict Scale (O’Connor 1995)
(Cronbach’s a5 0.76).
Exposure to PSA Information. We asked men how much they had heard, read,
or seen about prostate cancer over the past year.
PSA Discussion and Screening Decision. We asked men whether they had
discussed PSA screening with a health professional in the past year
and about their screening behavior 12 months after exposure to the
intervention.
Statistical Analyses
To test the study hypotheses, first, we conducted regression analyses to test for
differences between the intervention and control groups in the 12-month
outcomes. We used linear regression models for the ‘‘3-item PSA is a decision’’
composite score and satisfaction with level of involvement, and logistic re-
gression models for the preferred and actual levels of involvement and
concordance between the two. Each regression model included the sociode-
mographic and psychosocial variables described above. We used multiple-
imputation techniques outlined by Schafer (1997) to impute missing data for
predictor variables to ensure proper inference to all members of the target
population (missing data for most items were 5 percent or less). Missing values
for outcome measures were not imputed.
We also examined patterns of change in the outcome variables across
the entire study period (baseline to 12 months) for the two groups (interven-
tion and control). To analyze the repeated measurements across the multiple
time points (baseline, 6, and 12 months), we used generalized estimating
equations (GEE) to account for the potential correlation between observations
within communities and over time (Liang and Zeger 1986). For the GEE
models, we included a time, group (intervention versus control), and time-
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by-group interaction to allow us to determine whether the two groups differed
in patterns of change over time. Because one item in this ‘‘PSA is a decision’’
composite score appeared only in the 12-month survey, we fit GEE models for
individual items rather than for the composite score. However, we used the
composite score for the linear regression model at 12 months as noted above.
RESULTS
Participant Characteristics
As shown in Figure 1, a total of 584 men completed the baseline survey
(n 5 361 intervention; n 5 223 control). For the 6-month survey, 107 of the 125
Figure 1: Sample Distribution by Intervention Group and Time Point
Notes. Baseline numbers are the denominators in all cases.
RR, response rate.
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PO baseline participants completed it (response rate [RR] 5 86 percent); 167
of the 236 MH baseline participants completed it (RR 5 71 percent), and 118
of the 223 control baseline group participants completed it (RR 5 53 percent).
At 12 months, we sent the follow-up survey to all 584 baseline participants.
RRs were as follows: PO 5 89 men (RR 5 71 percent); MH 5 165 (RR 5 70
percent); and control 5 122 (RR 5 55 percent).
This paper focuses primarily on 12-month outcomes, which include men
who completed the baseline and 12-month surveys. We compared the char-
acteristics of men who completed the 12-month survey with those of men lost
to follow-up at this point. In the intervention and control groups, men who
dropped out were more likely to be black, less educated, and younger (po.05).
Baseline characteristics of the final (12 month) sample are presented in
Table 1. The intervention and control groups differed significantly in terms of
age and race. The MH group had significantly lower knowledge than the PO
group and control group and higher income than the control group, and they
were significantly less likely to have a personal doctor than the PO group. The
PO group had a PSA test more recently than the control group.
Belief That PSA Screening Is a Decision
Based on a multiple linear regression model of continuous scores on the ‘‘be-
lief that PSA screening is a decision’’ scale, participants in both the PO and
MH groups had significantly greater beliefs that PSA screening is a decision at
12 months than control group respondents (po.001; Table 2). The results also
suggest that black men were less likely than white men to believe screening is a
decision. Higher income, higher knowledge, and either never having a PSA
test or having a PSA test more than a year ago were associated with greater
belief that PSA screening is a decision. Men who had discussed the PSA with a
health professional in the past year, those who had seen a lot of information
about prostate cancer, and those with higher self-efficacy for communication
with a physician were less likely to believe that PSA screening is a decision.
To examine changes in beliefs over time, we tested logistic GEE models
for agreement with the three ‘‘PSA screening is a decision’’ items that were
available at all three time points. The first model explored change in agree-
ment with the statement ‘‘It is okay to decide not to have a PSA test after
learning the facts.’’ The time-by-group interaction was significant (po.001),
indicating that agreement with this item changed differentially between the
control and intervention groups. At baseline, the three groups had similar
levels of agreement (p4.05). At 6 months, agreement with the statement
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among respondents in both intervention groups had risen substantially and it
remained elevated at 12 months. In contrast, agreement levels decreased
slightly over time in the control group and were significantly lower than
those in either intervention group at both 6 and 12 months (po.001). The
two intervention groups did not differ significantly at any time point (p4.05)
(Figure 2).
Table 1: Baseline Demographic Characteristics of Participants by Study











po0.05N (%) N (%) N (%)
Age, mean (SD) 69 (8) 63 (11) 57 (11) PO-MH, PO-C, MH-C
Black race 8 (9) 53 (32) 62 (51) PO-MH, PO-C, MH-C
Married 68 (76) 135 (82) 98 (80)
Education
College or more 53 (60) 95 (58) 82 (67)
Some college 21 (24) 31 (19) 26 (21)
High school or less 8 (9) 28 (17) 12 (10)
Annual household income
U.S.$60,000 or more 37 (42) 76 (46) 16 (13) MH-C
U.S.$40,000–
U.S.$59,999
20 (22) 37 (22) 23 (19)
oU.S.$39,999 16 (18) 37 (22) 76 (62)
Health status
Excellent/very good 55 (62) 92 (56) 72 (59)
Good 21 (24) 54 (33) 41 (34)
Fair/poor 9 (10) 17 (10) 8 (7)
Have a personal physician 77 (87) 128 (78) 107 (88) PO-MH
Most recent PSA test
41 year 14 (16) 27 (16) 26 (21) PO-C
6 months–1 year 32 (36) 51 (31) 39 (32)
o 6 months 29 (33) 49 (30) 27 (22)
Never 8 (9) 25 (15) 27 (22)
Have had cancer other
than prostate cancer
19 (21) 31 (19) 16 (13)
Knowledge of prostate
cancer, mean (SD)
4 (2) 3 (2) 4 (2) PO-MH, MH-C
Perceived risk of prostate cancer
Very/somewhat high 19 (21) 26 (16) 25 (20)
Moderate 31 (35) 63 (38) 42 (34)
Very/somewhat low 22 (25) 31 (19) 39 (32)
Self-efficacy, mean (SD) 3 (1) 3 (1) 3 (1)
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(a)
(b)
Figure 2: Belief That PSA Screening Is a Decision over Time, by Group
Notes. (a) Time  intervention group (po.001) (N 5 315).
(b) Time  Intervention group (p 5 .006) (N 5 315).
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Second, we found a significant time-by-group interaction with respect to
the statement ‘‘Every man should have a regular PSA test’’ (p 5 .006). Inter-
vention and control groups’ beliefs were similar at baseline (p4.05). At 6
months, participants’ agreement that ‘‘every man should have a regular PSA
test’’ had declined among both intervention groups, whereas the control
groups’ agreement was unchanged. The control group had significantly
greater agreement with this item at 6 months than the PO (po.001) and MH
(p 5 .002) groups; the PO group had slightly lower agreement than the MH
group (p 5 .053). The difference between the intervention and control groups
remained significant at 12 months (PO versus control [p 5 .004] and MH
[po.001]); however, the difference between the two intervention groups dis-
appeared (p 5 .523).
Finally, we found no significant time-by-group interaction for the final
item (‘‘Every man should decide whether or not a PSA test is right for him’’;
p 5 .579) (not shown). Therefore, we removed the interaction and reran the
model. The results indicated that the PO and MH groups had greater agree-
ment than the control group (p 5 .001), and the levels of agreement rose over
time (po.001). Agreement ranged from 52 percent (baseline) to 78 percent (12
months) for the PO group, 53–75 percent for the MH group, and 43–57
percent for the control group.
Change in Knowledge after Exposure to the Intervention
For both intervention groups, knowledge increased significantly from baseline
to 12 months for all but one of the 10 items (not shown). For the control group,
knowledge did not change significantly except for a significant decrease in
awareness that men are most likely to die from heart attack and stroke. On all
except the item indicating that men can have cancer even with a normal PSA
test, change in knowledge differed between the intervention groups and the
control group (elsewhere, we report that our intervention resulted in signifi-
cant and sustained increases in prostate cancer knowledge levels over the
12-month study period using multivariate analysis; McCormack et al. 2009).
Preferred and Actual Levels of Involvement in the PSA Decision
Figure 3 depicts men’s preferred level of involvement in the PSA screening
decision at baseline and 12 months. Both intervention groups changed sig-
nificantly over time in terms of preferred level of involvement (PO: p 5 .009;
MH: p 5 .002). At 12 months, a higher percentage of men than at baseline
preferred sharing responsibility or making the decision themselves (PO group,
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81 percent at baseline and 94 percent at follow-up; MH, 76 and 88 percent;
controls, 75 and 80 percent). The control group differences over time were not
significant. Figure 3 also shows (right-hand bars) the proportion of each group
who engaged in shared or autonomous decision making at 12 months.
Results from logistic regression analyses of 12-month preferred and ac-
tual levels of involvement appear in Table 2. At 12 months, participants in
both intervention groups were more likely than the control group to prefer
more active involvement in decision making about PSA screening. Men who
received the PO intervention materials were six times more likely than control
group participants to prefer active involvement. Other significant correlates of
a preference for more active involvement were younger age, lower self-
efficacy, and having a PSA discussion with a physician.
At 12 months, those in the MH intervention group were significantly
more likely than control group participants to report actual involvement in the
Figure 3: Preferred and Actual Levels of Involvement in PSA Decision by
Study Group at Baseline and 12 Months
Note. N 5 370 for preferred level of involvement and N 5 346 for actual level of involvement.
Comparisons of preferred involvement at baseline versus 12 months: Prostate Only (p 5 .009),
Men’s Health (p 5 .002), and control (p 5 .265).
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PSA decision (Table 2). The PO group tended toward greater involvement
than the control group, but this difference was not statistically significant
(p 5 .064). Other predictors of actual involvement in decision making were
having discussed PSA screening with a physician, greater decisional uncer-
tainty, and lower self-efficacy.
Concordance between Preferred and Actual Levels of Involvement in PSA Decision
We explored concordance between men’s preferred and actual levels of in-
volvement in the PSA decision at 6 and 12 months. At 6 months, we examined
concordance only among participants who had had a discussion with their
doctor about PSA screening (given the skip pattern in the survey); the 12-
month analyses included all respondents who answered the baseline and 12-
month surveys. At 6 months, levels of concordance by group were as follows:
PO, 73 percent; MH, 71 percent; and control, 59 percent. At 12 months, these
values were, respectively, 56, 51, and 51 percent.
A logistic regression analysis showed that, after controlling for other
factors, participation in the intervention groups was a significant predictor of
concordance at 6 months (not shown). Relative to the control group, men in
the PO group were more likely to be concordant (OR [95 percent CI] 5 7.81
[1.78, 34.23], p 5 .007); the same was true for those in the MH group (OR [95
percent CI] 5 4.41 [1.38, 14.07], p 5 .012). However, at 12 months, partici-
pation in the interventions was no longer a significant predictor of concor-
dance, based on analyses using the full sample.
Actual Screening Decision and Satisfaction Levels
At 12 months, all participants were asked if they had a PSA test in the last year
(including those who had a discussion with their provider as well as those who
did not). The percentages of men receiving a PSA test during the prior 12
months (i.e., the study period) were PO, 71 percent (n 5 60); MH, 61 percent
(n 5 93); and control, 64 percent (n 5 76). Using a logistic regression model
(n 5 355, not shown), we predicted the probability of receiving a PSA test in
the prior 12 months based on intervention group, actual involvement in PSA
screening decision, and the other factors shown in Table 2. The intervention
groups did not differ significantly relative to the control group in their like-
lihood of getting a PSA test. The following factors were associated with greater
odds of having a PSA test: older age (po.001), excellent/very good or good
health status (versus fair/poor) (p 5 .033 and .013, respectively), greater pros-
tate cancer knowledge (p 5 .041), having a discussion with doctor (po.001),
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and greater decisional conflict (p 5 .019). Level of actual involvement in the
PSA screening decision at 12 months was not a significant predictor, but the
results suggest a general trend: those for whom the doctor made the decision
or who reported that they engaged in shared decision making were more likely
to receive a PSA test than those making the decision themselves (p 5 .068 and
.052, respectively).
Based on descriptive statistics, the intervention and control groups did
not differ in terms of satisfaction with their testing decision at 12 months (the
only point in time this question was asked). Using a logistic regression analysis
(n 5 338, not shown), we then found that neither participation in the inter-
vention nor concordance between preferred and actual levels of involvement
predicted being very satisfied with level of involvement in the decision.
CONCLUSIONS
Our IDM intervention was associated with greater recognition of PSA testing
as a decision to be made, levels of knowledge, and both preferred and actual
levels of involvement in decision making, but had no impact on screening
decisions. Ensuring that patients and their families are involved in the care
process is a key aspect of patient-centered communication, as advocated by
the Institute of Medicine (2001). Through this involvement and communica-
tion process, personal values and preferences can be considered and taken
into account when medical decisions are made. Considering personal pref-
erences and values is particularly important for decision making when phy-
sicians and patients face uncertainty about the benefits and risks of medical
interventions and decisions are therefore ‘‘preference sensitive’’ (O’Connor,
Légaré, and Stacey 2003).
The study has some limitations. First, we had some baseline differences
between the intervention and control groups. We also experienced differential
attrition from the study; more control group members and certain subgroups
were lost to follow-up. A possible implication of losing younger and less
educated men over time is a lower level of actual level of involvement in
decision making, because these groups tend to be less autonomous in this
process. Given that this was a community-based study, the IDM measures
were not assessed immediately following the intervention, and the data are
self-reported.
IDM will become even more critical than in the past as reviews
of clinical evidence and comparative effectiveness initiatives emerge, giving
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patients more responsibility for decisions related to screening and therapeutic
options. For example, the USPSTF now makes the following recommendation
regarding breast cancer screening: ‘‘that physicians and patients discuss the
potential harms and benefits when making the individual, personalized de-
cision about when to start screening’’ (Petitti and Calogne 2010). However,
patients must first recognize that they have decisions to make, whether about
cancer screening or other clinical issues. Making this point was a key goal of
our intervention.
Promoting IDM about cancer screening is challenging given the broad
support for such screening in general in the United States. A national survey
found widespread belief that routine cancer screening is ‘‘almost always a
good idea’’; recognition of the risks associated with overtesting and overtreat-
ing is limited (Schwartz et al. 2004). Thus, our intervention’s message that
screening may not necessarily be the right choice in all circumstances is
counterintuitive. In our study, formative research participants often did not
comprehend the potential downsides of testing (only the potential advanta-
ges). This phenomenon is likely a result, in part, of the plethora of nonev-
idence-based messages to which the public is exposed. Despite the somewhat
unbalanced presentation of the message, changing actual behaviors is typi-
cally difficult.
Credible health communication messages are needed to help consumers
understand that medicine is imperfect and that they have a role to play in
making health-related decisions. More attention is needed to help the general
public understand prevention and clinical preventive services and the role of
evidence in developing recommendations. Our findings have important im-
plications for how to convey information about topics to which the USPSTF
has given an ‘‘I’’ Recommendation grade (Insufficient Evidence to Make a
Recommendation) and, possibly, ‘‘C’’ Recommendations (Recommendations
against Screening) as well. Given the general proscreening climate, IDM
messages for ‘‘I’’ and ‘‘C’’ grades need to achieve the appropriate balance of
information about the potential advantages and disadvantages of screening.
These findings are particularly timely given the late 2009 controversy regard-
ing the release of breast cancer guidelines to the public and the ensuing public
confusion.
Finding that men who discussed PSA screening with their physician (rel-
ative to those who did not) were less likely to believe that PSA screening is a
decision raises intriguing questions about the current state of patient–provider
communication. It may be that doctors present PSA screening as standard
procedure rather than as a choice, which goes against USPSTF recommenda-
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tions. Understandably, clinicians face challenges in promoting IDM: time con-
straints, conflicting guidelines, and uncertainty about the best way to present
complex medical information to patients (Guerra et al. 2007). Future research
could explore physician attitudes about USPSTF recommendations——particu-
larly those that recommend IDM——and the association between physician at-
titudes and barriers with the recommendations they make to patients.
In this study, men with greater decisional uncertainty were more likely
to report greater levels of involvement in decision making and also greater
satisfaction with their level of involvement. One explanation may be that men
who are less certain about the decision deliberate more about their values and
preferences and talk more to their clinician and, ultimately, are more actively
involved in the decision and more satisfied with their level of involvement.
This notion is consistent with prior research (O’Connor et al. 2006). Thus,
some level of uncertainty may be beneficial to promoting informed decisions,
as long as the uncertainty is managed appropriately.
The IDM intervention in this study increased concordance between
preferred and actual levels of participation among the subset of participants
who discussed PSA screening with their physician at the 6-month follow-up.
However, this finding did not hold at 12 months when looking at a larger
sample, including both men who did and did not have a discussion. We cannot
be sure based on this study, but having a discussion may well influence men’s
perceptions of their actual level of participation. Additional research in both
community and clinical settings——including studies of patient–provider inter-
actions and specifically how decisions are being made——is needed to better
understand the communication interaction (Epstein and Street 2007). Such
research, which should include multiple methods (e.g., observation, inter-
views, surveys), may also reveal barriers to concordance between patients’
preferred and actual levels of involvement in decision making and shed light
on how decision aids can most effectively enhance communication.
When measuring patient-centered communication, some have argued
that the quality of the patient–provider interaction and the decision itself de-
serves greater focus (Sepucha, Fowler, and Mulley 2004); level of involvement
may warrant relatively less attention in the future. Addressing ‘‘quality’’ and
‘‘satisfaction’’ questions more fully may be appropriate given that people’s
preferences have been shown to change over time for various reasons (Slovic
1995). Some people simply prefer to be less involved (Woolf et al. 2005).
Community-based interventions can inform and educate men about
issues surrounding the PSA decision and promote IDM before they face the
screening decision in the clinical setting. Communicating health-related in-
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formation in a setting that people trust and when they have time to process the
information is a key benefit of community-based health interventions (Driscoll
et al. 2008). Reaching individuals who are unlikely to participate in clinical
IDM interventions because of barriers related to individual socioeconomic
status (Isaacs and Schroeder 2004), lower health literacy (Braveman et al.
2005), and fewer problem-solving skills (Ross and Wu 1995) is an additional
benefit. To facilitate adoption, the intervention we developed was low cost and
fairly easy to implement. A two-pronged approach that combines clinician
training in IDM principles with patient education and empowerment tech-
niques may have even greater impact on IDM adoption than focusing on only
one or the other. Health information technology and other tools (e.g., decision
aids) offer great promise in facilitating this two-pronged approach.
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